[Genome instability and bleomycin sensitivity test].
Estimation of individual susceptibility to mutagens is often a part of epidemiological studies monitoring the appearance of malignant disease in different populations. Genome exposure to mutagens can lead to DNA damage. The rate of damage depends on individual differences in response, which are usually associated with differences in DNA repair capacity. Cytogenetic studies have shown that the genome of tumour cells is less stable than normal cells and therefore accumulates more damage. Tumour patients show a higher frequency of chromatid and chromosomal aberrations and a predisposition to certain types of tumours. One of the common biomarkers used in monitoring tumour appearance and changed response to DNA damage is the bleomycin test. In its active form, bleomycin (glycopeptid) is a radiomimetic cytostatic that can damage the DNA molecule and cause multiple single and double strands. The bleomycin test is simple and inexpensive, and is based on scoring chromatid breaks in lymphocytes in vitro exposed to bleomycin during the late G2 phase of the cell cycle. This review looks into different factors that may affect test results and discusses its wide implementation in studies of genome instability usually caused by a combination of factors.
Milić
Mirta
M
Institut za medicinska istrazivanja i medicinu rada, Zagreb, Hrvatska. mmilic@imi.hr
D001761:Bleomycin / Q000494:pharmacology*; D002842:Chromatids / Q000187:drug effects; D004260:DNA Repair / Q000187:drug effects; D042822:Genomic Instability / Q000187:drug effects*; D006801:Humans; D009152:Mutagenicity Tests; D009153:Mutagens / Q000494:pharmacology*; D009369:Neoplasms / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000187:drug effects; D014178:Translocation, Genetic / Q000187:drug effects
D009153:Mutagens; D001761:Bleomycin